Mechanistically, EGFRC797S parallels the acquired Bruton tyrosine kinase (BTK) C481S mutation, which is observed in patients with chronic lymphocytic leukemia who develop acquired resistance to therapy with ibrutinib, an irreversible BTK inhibitor. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.